- PR Newswire•19 hours ago
LOS ANGELES, Dec. 2, 2016 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Earl Warren Brien, M.D., a noted sarcoma surgeon, industry consultant, and private healthcare investor, to its Board of Directors. "Dr. Brien is a healthcare leader with clinical and strategic experience at the highest level," said Steven A. Kriegsman, CytRx's Chairman and CEO.
- TheStreet.com•4 days ago
CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.
- PR Newswire•4 days agoCytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas
LOS ANGELES, Nov. 29, 2016 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR) today announced positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to investigator's ...
CYTR : Summary for CytRx Corporation - Yahoo Finance
CytRx Corporation (CYTR)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.48 x 18800|
|Ask||0.59 x 100|
|Day's Range||0.48 - 0.53|
|52 Week Range||0.41 - 3.66|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.58|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|